Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 610

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus

Open access
Mougiakakos, Dimitrios, Krönke, Gerhard, Völkl, Simon, Kretschmann, Sascha, Aigner, Michael, Kharboutli, Soraya, Böltz, Sebastian, Manger, Bernhard, Mackensen, Andreas, Schett, Georg·2021·New England Journal of Medicine

Abstract

Systemic Lupus ErythematosusTo the Editor: Systemic lupus erythematosus (SLE) is a severe autoimmune disease that predominantly affects young women.SLE is characterized by the formation of autoantibodies and immune complex-mediated inflammation and organ damage.Although autoreactive B cells play a key role in the pathogenesis of SLE, B-cell depletion by antibodies has only limited therapeutic efficacy.1 This paradox has been attributed to the inaccessibility and persistence of autoreactive B cells within lymphatic organs and inflamed tissues 2 or the pathologic role of CD20-negative plasma cells, which may act as an additional source of autoantibodies in patients with SLE. 3 Chimeric antigen receptor (CAR)-modified T cells that have been genetically engineered to recognize CD19 and other B-cell surface antigens have emerged as a powerful tool for the treatment of relapsed or refractory B-cell cancers.4 This technological breakthrough, together with recent convincing data on the role of B cells in disease pathogenesis derived from preclinical lupus models, 5 provides a rationale for the use of CAR T-cell therapies in patients with SLE.We report here on the use of autologous CD19 CAR T cells in the treatment of an autoimmune disease.A 20-year-old woman with severe and refractory SLE presented with active lupus nephritis (World Health Organization class IIIA, indicating focal proliferative disease with active lesions), nephrotic syndrome, pericarditis, pleurisy, rash, arthritis, and a history of Libman-Sacks endocarditis.Previous treatments with hydroxychloroquine, high-dose glucocorticoids, cyclophosphamide, mycophenolate mofetil, and tacrolimus, as well as the B-cell-targeting therapies belimumab and rituximab, did not control symptoms, deplete B cells, or abrogate autoimmunity (Fig. S1 in the

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmc2107725

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 610

Metadata

Authors
Mougiakakos, D., Krönke, G., Völkl, S., Kretschmann, S., Aigner, M., Kharboutli, S., Böltz, S., Manger, B., Mackensen, A., & Schett, G.
Venue
New England Journal of Medicine
Published
2021-08-05
Volume
385
Issue
6
Pages
567-569
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3190820492
Cited by
610
References
5
FWCI
46.69
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. https://app.cochat.ai/papers/10.1056/nejmc2107725
The paper
Mougiakakos, D., Krönke, G., Völkl, S., Kretschmann, S., Aigner, M., Kharboutli, S., Böltz, S., Manger, B., Mackensen, A., & Schett, G. (2021). CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. New England Journal of Medicine. https://doi.org/10.1056/nejmc2107725

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.